GMED Globus Medical Inc Class A

Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference

Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference

Monday, March 10, 2025 at 4:30 pm Pacific Time

AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 4:30 pm PT.

Interested parties can access the live and archived webcast of the presentation in the “News & Events”, “Events & Webcasts” section of the Globus Medical investor relations website at .  

About Globus Medical, Inc. 

Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, regenerative biomaterials and enabling technologies. Additional information can be accessed at .  

Investor contact: 

Brian Kearns 

610-930-1800 

 

Media contact: 

Moran Chavez 

 



EN
06/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Globus Medical Inc Class A

Globus Medical Inc: 1 director

A director at Globus Medical Inc sold 4,000 shares at 88.850USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

Globus Medical Reports Third Quarter 2025 Results

Globus Medical Reports Third Quarter 2025 Results AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share (“EP...

 PRESS RELEASE

Globus Medical Schedules Third Quarter Earnings Release and Conference...

Globus Medical Schedules Third Quarter Earnings Release and Conference Call AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after the market close on Thursday, November 6, 2025. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference...

 PRESS RELEASE

Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive...

Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures. The ANTHEM™ Elbow Fracture System is designed to offer surgeons anatomically contoured plates to treat a variety of fractures, regardless of severity or complexity, with a simplified workflow. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch